Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

CAROTID STENTS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Carotid Stents in Thousand Units and US$ Million. The report provides separate comprehensive analytics for the US, Europe and Rest of World. Annual forecasts are provided for each region for the period of 2004 through 2012. The report profiles 10 companies including many key and niche players worldwide such as Abbott Vascular, Boston Scientific Corporation, ev3, Inc., Johnson & Johnson, Cordis Corporation, Kensey Nash Corporation, and Medtronic, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1548
Price : $3950
Companies : 10
Pages : 148
Date : March 2008
Market Data Tables : 59

Complimentary Report Insights:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  CAROTID STENTS (Complete Report) Pages : 148   | $3950
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
Quantitative Techniques & Analytics.....I-2
  
   Product Definitions and Scope of Study.....I-3
Carotid Stents.....I-3
  
II. EXECUTIVE SUMMARY34$2250
  1. Global Market Overview and Analysis.....II-11 $100  
   Carotid Stents – A Nascent Market.....II-1
Current and Future Analysis.....II-1
US – Picking Pace.....II-1
1$100
  2. Market Dynamics.....II-23 $300  
   Factors Driving Carotid Stents Market.....II-2
Clinical Trials & Regulatory Approvals to Accelerate Adoption.....II-2
Broader Application of CAS.....II-2
Benefiting From Less-Invasive Nature of Procedure.....II-2
Acceptance by Various Medical Specialties.....II-2
1$100
   Market Challenges.....II-3
Absence of Sufficient Clinical Data.....II-3
Surgeons Wary of High-Risk CAS Procedures.....II-3
Reimbursement Coverage Issue Hurdles Widespread Adoption.....II-3
Fighting for CAS Domain.....II-3
1$100
   Training and Certification of Surgeons – A Major Hurdle.....II-4
Stenting Procedure for Transient Ischemic Attacks – A Continuing Dilemma.....II-4
1$100
  3. Competitive Scenario.....II-51 $300  
   Table 1: Worldwide Carotid Stents Market (2006-2007E): Market Share of Leading Players by Revenues for Boston Scientific, Abbott Vascular/Guidant, Johnson & Johnson/Cordis, Medtronic and Others (includes corresponding Graph/Chart).....II-5
1$300
  4. Product Overview.....II-67 $550  
   Carotid Stents – An Introduction.....II-6
How is Carotid Stenting Helpful?.....II-6
Carotid Stents – A Viable Alternative to Surgical Procedures.....II-6
1$100
   Carotid Stenting Lowers Depression Symptoms!!!.....II-7
Embolic Protection Devices.....II-7
Filter-Based EPD Systems.....II-7
Balloon Occlusion Devices.....II-7
1$100
   Basic Carotid Stents Products.....II-8
Stent Design.....II-8
Carotid Stents of Major Companies Available in the Market.....II-8
1$100
   Carotid Stents Under Development.....II-9
Diagnosis of Carotid Artery Blockage.....II-9
1$100
   Eligibility Criteria for Carotid Stenting Procedure.....II-10
Potential Candidates for Carotid Stenting.....II-10
Patients with High Surgical Risk.....II-10
Non-Candidates for Carotid Stenting.....II-10
Risk Factors Associated with Carotid Stenting Procedures.....II-10
1$100
   Carotid Artery Stenting (CAS) - The Procedure.....II-11
Catheter Insertion Via Femoral Artery.....II-11
1$100
   Advantages of the Procedure.....II-12
Post-Stenting Complications.....II-12
1$100
  5. Overview of Cardiac Diseases.....II-135 $600  
   Cerebrovascular Disease.....II-13
Carotid Artery Disease.....II-13
Major Symptoms.....II-13
Carotid Artery Stenosis.....II-13
1$100
   Atherosclerosis.....II-14
Treatment Procedures for Carotid Artery Disease.....II-14
Carotid Endarterectomy (CEA).....II-14
Drawbacks of CEA Procedure.....II-14
1$100
   Carotid Artery Stenting (CAS).....II-15
CAS Versus CEA.....II-15
1$100
   Table 2: Worldwide Carotid Interventions (2006-2008E)): Percentage Breakdown of Number of Procedures for Carotid Endarterectomy and Carotid Stenting (includes corresponding Graph/Chart).....II-16
Comparative Study of CAS and CEA Devices.....II-16
Benefits of CAS over CEA.....II-16
1$300
   Drawbacks for CAS Penetration.....II-17
Risks Associated with CEA and CAS.....II-17
1$100
  6. Major Clinical Trials/Studies.....II-185 $500  
   Clinical Trials – Key to Higher Adoption of Carotid Stents.....II-18
Major Clinical Trials & Stent Devices Used.....II-18
1$100
   Guidant’s CAPTURE Study.....II-19
CAPTURE Study Results Hold Promise for Asymptomatic Patients.....II-19
1$100
   Boston Scientific’s BEACH Trial.....II-20
Abbott’s ACT I Trial.....II-20
CREST Clinical Trial.....II-20
1$100
   CREST Closes Lead-in and Randomized Phase Recruitment.....II-21
J&J’s SAPPHIRE Clinical Trial.....II-21
SAPPHIRE Study Proves Effectiveness of CAS in High-Risk Patients.....II-21
1$100
   Other Trials.....II-22
Medtronic’s MAVErIC Trials Validate the Efficiency of Exponent Carotid Stent.....II-22
University of Massachusetts Conduct CAS Efficacy Study in Elderly Patients.....II-22
CaRESS Study.....II-22
1$100
  7. Product Launches/Approvals.....II-235 $500  
   KNC Obtains Expanded CE Mark Clearance for TriActiv® ProGuard™.....II-23
FDA Approves Protege® RX Carotid Stent from ev3.....II-23
1$100
   Abbott Introduces Emboshield® PRO Embolic Protection System in Europe.....II-24
Cordis Gains FDA Approval for PRECISE® & ANGIOGUARD® Devices.....II-24
Medtronic Obtains CE Mark Approval for Exponent® RX Carotid Stent.....II-24
1$100
   FDA Approves Boston Scientific’s FilterWire EZ™ Embolic Protection System.....II-25
Abbott's Xact® Carotid Stent Receives FDA Approval.....II-25
EndoTex’s NexStent™ Receives CE Mark Approval.....II-25
KNC Seeks FDA Approval for TriActiv LFX Trial.....II-25
1$100
   Guidant's RX ACCULINK™ Carotid Stent System Gets FDA Clearance.....II-26
ev3’s Protege GPS Receives CE Mark Approval.....II-26
Medtronic’s Interceptor® PLUS Carotid Filter System Receives CE Mark Approval.....II-26
Guidant Unveils RX Accunet Embolic Protection System in European Market.....II-26
1$100
   Guidant Rolls Out ACCULINK™ Carotid Stent System for European Market.....II-27
1$100
  8. Recent Industry Activity.....II-282 $200  
   Boston Scientific Acquires EndoTex.....II-28
Boston Scientific and Guidant Merge Operations; Abbott Acquires Guidant’s Vascular
  Business.....II-28
1$100
   Lumen Commences EPIC Feasibility Study.....II-29
Boston Scientific Exclusively Distributes EndoTex’s NexStent™ Carotid Stent.....II-29
1$100
  9. Focus on Select Players.....II-303 $300  
   Abbott Vascular (US).....II-30
Boston Scientific Corporation (USA).....II-30
1$100
   ev3, Inc. (USA).....II-31
Johnson & Johnson (USA).....II-31
Cordis Corporation (USA).....II-31
1$100
   Kensey Nash Corporation (USA).....II-32
Medtronic, Inc. (USA).....II-32
1$100
  10. Global Market Perspective.....II-33   
   Table 3: World Recent Past, Current & Future Analysis for Carotid Stents by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....II-33

Table 4: World 9-Year Perspective for Carotid Stents by Geographic Region – Percentage Breakdown by Number of Carotid Stent Procedures for US, Europe and Rest of World Markets for Years 2004, 2007 & 2012 (includes corresponding Graph/Chart).....II-33
1$300
   Table 5: World Recent Past, Current & Future Analysis for Carotid Stents by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....II-34

Table 6: World 9-Year Perspective for Carotid Stents by Geographic Region – Percentage Breakdown by Annual Revenues for US, Europe and Rest of World Markets for Years 2004, 2007 & 2012 (includes corresponding Graph/Chart).....II-34
1$300
III. MARKET21$1950
  1. The United States.....III-114 $1175  
   A. Market Analysis.....III-1
Overview.....III-1
Current and Future Analysis.....III-1
Factors Affecting Growth.....III-1
Reimbursement Scenario for CAS.....III-1
1$100
   Restricted Reimbursement Coverage Limits CAS Penetration .....III-2
CMS Proposes Expanded Reimbursement Coverage for Carotid Stenting.....III-2
1$100
   Absence of Regulatory Approvals – A Major Challenge.....III-3
Clinical Trials – Key to Higher Adoption of Carotid Stents.....III-3
Latent Demand.....III-3
Key Statistics.....III-3
Major Carotid Stents & EPDs in the Market.....III-3
1$100
   US Carotid Stents Market – A Gradual Growth.....III-4 1$100
   Table 7: Carotid Interventions in the US (2006-2008): Percentage Breakdown of Number of Procedures by Carotid Endarterectomy and Carotid Stenting (includes corresponding Graph/Chart).....III-5
Trends and Issues.....III-5
Convenience in Deployment & Use – Critical for Higher Adoption.....III-5
Rapid Exchange Capabilities Facilitate Effective Control Over Procedures.....III-5
Carotid Stents Assume the Role of Memory Boosters.....III-5
1$150
   Competitive Landscape.....III-6
Table 8: US Carotid Stents Market (2006-2007): Market Share of Leading Players by Revenues for Boston Scientific, Guidant, Cordis/J&J, Medtronic and Others (includes corresponding Graph/Chart).....III-6
1$150
   Product Launches/Approvals.....III-72$200
   Strategic Corporate Developments.....III-91$100
   Focus on Select Players.....III-10
Abbott Vascular.....III-10
1$100
   Boston Scientific Corporation.....III-11
ev3, Inc......III-11
1$100
   Johnson & Johnson.....III-12
Cordis Corporation.....III-12
Kensey Nash Corporation.....III-12
1$100
   Medtronic, Inc......III-13
B. Market Analysis.....III-13
Table 9: US Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-13
1$150
   Table 10: US Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-14
1$150
  2. Europe.....III-155 $475  
   A. Market Analysis.....III-15
Current and Future Analysis.....III-15
European Carotid Stents Market – An Overview.....III-15
ELOCAS Study.....III-15
CEA Versus CAS.....III-15
1$100
   Table 11: European Vascular Interventions Market (2004-2006E): Percentage Breakdown by Number of Procedures for Carotid Artery Stenting and Carotid Endarterectomy (includes corresponding Graph/Chart).....III-16
Product Launches/Approvals.....III-16
2$300
   Strategic Corporate Development.....III-181$100
   B. Market Analytics.....III-19
Table 12: European Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-19

Table 13: European Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-19
1$150
  3. Rest of World.....III-202 $200  
   A. Market Analysis.....III-20
Current and Future Analysis.....III-20
Carotid Stenting Scenario in India.....III-20
1$100
   B. Market Analytics.....III-21
Table 14: Rest of World Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Number of Carotid Stent Procedures in Thousands for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-21

Table 15: Rest of World Recent Past, Current & Future Analysis for Carotid Stents Market Independently Analyzed with Annual Revenues in US$ Million for Years 2004 through 2012 (includes corresponding Graph/Chart).....III-21
1$150
IV. COMPETITIVE LANDSCAPE 85$995
  
Total Companies Profiled: 10 (including Divisions/Subsidiaries - 14)

Region/Country                 Players

The United States                 12
Europe                             2
     Italy                         1
     Rest of Europe                1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign